Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNIPPS: Riluzole in MSA and PSP
NCT00211224Phase 3Terminated
- Sponsor
- King's College London
- Start
- Apr 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) comparing Riluzole with Placebo (2 arms). Primary endpoint: Survival at 36 months. Started Apr 2000; status: terminated.
02
Drugs
riluzole
03
Conditions
multiple system atrophy (MSA)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT00211224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211224.